Author

K. R. Jordan

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Physiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Organism:human· 4 Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Assay:proteomics· 2 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

B. G. Bitler· 4 shared E. R. Woodruff· 2 shared K. Behbakht· 2 shared M. R. Moroney· 2 shared Z. L. Watson· 2 shared A. Clauset· 1 shared A. D. Jeong· 1 shared A. J. Polotsky· 1 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

B. G. Bitler

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Combination CDC-like kinase inhibition (CLK)/Dual-specificity tyrosine-regulated kinase (DYRK) and taxane therapy in CTNNB1-mutated endometrial cancer

B. R. Corr, M. R. Moroney, E. R. Woodruff, Z. L. Watson, K. R. Jordan, T. Danhorn, C. Bailey, R. J. Wolsky, B. G. Bitler

This paper evaluates SM08502, a CLK/DYRK inhibitor, as a single-agent and in combination with paclitaxel for CTNNB1-mutated endometrial cancer, showing synergistic effects and tumor volume reduction in vitro and in vivo.

bioRxiv · Apr 4, 2023 · PreprintCancer Biology

Combinatory EHMT and PARP inhibition induces an interferon response and a CD8 T cell-dependent tumor regression in PARP inhibitor-resistant models

L. L. Nguyen, Z. L. Watson, R. Ortega, E. R. Woodruff, K. R. Jordan, R. Iwanaga, T. M. Yamamoto, C. A. Bailey, A. D. Jeong, S. Guntupalli, K. Behbakht, V. Gibaja, N. Arnoult, E. Chuong, B. G. Bitler

bioRxiv · Feb 23, 2023 · PreprintCancer Biology

The capacity of the ovarian cancer tumor microenvironment to integrate inflammation signaling conveys a shorter disease-free interval

K. R. Jordan, M. J. Sikora, J. E. Slansky, A. Minic, J. K. Richer, M. R. Moroney, J. C. Costello, A. Clauset, K. Behbakht, T. R. Kumar, B. G. Bitler

This study identifies an IL-6/IER3 inflammatory signaling axis linked to chemo-resistance in ovarian cancer by analyzing pre- and post-chemotherapy tumor microenvironment changes.

Clinical Cancer Research · Dec 1, 2020Peer-reviewedCancer Biology

Expression and T cell Regulatory Action of the PD-1 Immune Checkpoint in the Ovary and Fallopian Tube

J. Johnson, P. K. Sam, R. Asokan, E. Llerena Cari, E. S. Bales, T.-H. Luu, L. Perez, A. N. Kallen, L. Nel-Themaat, A. J. Polotsky, M. D. Post, D. J. Orlicky, K. R. Jordan, B. G. Bitler

This study shows PD-1 and its ligands are expressed by ovarian and fallopian tube cells, with functional implications for T cell regulation and immune privilege in reproductive tissues.

bioRxiv · Jun 6, 2020Physiology